• Should you Buy this Company on Earnings?

    By Mohsin Saeed - March 5, 2013 | Tickers: ALPMY.PK, DNDN, JNJ

    Dendreon Corp. (NASDAQ: DNDN) investors have been on a perpetual roller coaster ride due to shifting expectations from Provenge. The company reported its quarterly results the other day and beat Street estimates. However, Provenge faces severe competition from Astellas’ (NASDAQOTH: ALPMY) Xtandi and Johnson & Johnson’s (NYSE: JNJ) Zytinga. I believe that despite the recent positives it’s still too soon to be bullish on Dendreon, and I advise investors more »

  • Can this Bio-Pharmaceutical Rise Again?

    By Waqar Saif - February 14, 2013 | Tickers: ALPMY.PK, DNDN, JNJ

    Shares of Dendreon (NASDAQ: DNDN) have seen an epic decline due to weak sales numbers for its star drug Provenge. The drug has missed analyst expectations and has failed to justify high valuations for its creator. I believe the company is correctly priced at these levels and there is little room for an upside. In order to warrant better valuations in the future, company management should be focusing on strengthening more »

  • Regeneron's Vision for the Future

    By Jonathan Lim - August 27, 2012 | Tickers: ALPMY.PK, BAYRY.PK, REGN, RHHBY, SNY

    "Great company, but not at that price" is a line I use a lot these days. It sure can be tempting to deviate from a value-focused strategy, especially when all sorts of glamorous growth stories are commanding billion-dollar valuations and your Benjamin Graham cigarette-butt stocks aren’t featured on CNBC every day and aren’t sending you glossy annual reports full of exciting news. But I’m managing to stick more »